Shopping Cart
- Remove All
Your shopping cart is currently empty
Tozorakimab
Catalog No. T76972Cas No. 2376858-66-9
Alias MEDI-3506, MEDI3506, MEDI 3506
Tozorakimab (MEDI-3506) is a human immunoglobulin G1 monoclonal antibody targeting IL-33. It inhibits IL-33 signaling through ST2 and RAGE/EGFR, reduces inflammation and epithelial dysfunction, and can be used to study chronic obstructive pulmonary disease.
Tozorakimab
Tozorakimab
Catalog No. T76972Alias MEDI-3506, MEDI3506, MEDI 3506Cas No. 2376858-66-9
Tozorakimab (MEDI-3506) is a human immunoglobulin G1 monoclonal antibody targeting IL-33. It inhibits IL-33 signaling through ST2 and RAGE/EGFR, reduces inflammation and epithelial dysfunction, and can be used to study chronic obstructive pulmonary disease.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $298 | In Stock | |
| 5 mg | $778 | 7-10 days |
Bulk & Custom
Add to Cart
Questions
View MoreSelect Batch
Concentration:3.65 mg/mL
Purity:SEC-HPLC：96.03%
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | Tozorakimab (MEDI-3506) is a human immunoglobulin G1 monoclonal antibody targeting IL-33. It inhibits IL-33 signaling through ST2 and RAGE/EGFR, reduces inflammation and epithelial dysfunction, and can be used to study chronic obstructive pulmonary disease. |
| Targets&IC50 | IL-33:0.082 nM |
| In vitro | Tozorakimab had a > 10,000-fold higher potency for IL-33red than the lead mAb (33v20064) in a biochemical epitope competition assay (IC50=0.082 nM). [1] |
| In vivo | Female humanized IL-33 mice (6–10 weeks of age) were anaesthetized using isoflurane. Prophylactic intraperitoneal administration of Tozorakimab (0.1, 1.0, 3.0 and 10.0 mg/kg) dose-dependently inhibited IL-5 levels in bronchoalveolar lavage fluid (BALF) compared with the controls. [1] |
| Alias | MEDI-3506, MEDI3506, MEDI 3506 |
| Molecular Weight | 144.41 kDa |
| Cas No. | 2376858-66-9 |
Storage & Solubility Information
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Tozorakimab | purchase Tozorakimab | Tozorakimab cost | order Tozorakimab | Tozorakimab in vivo | Tozorakimab in vitro | Tozorakimab molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.